Genmab
Research Genmab (GMAB) on Bullrun: market cap USD 20.51B, P/E 27.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGMAB
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 20.51B
- P/E27.2
- Financial periodQ2 2026
- RevenueUSD 1.16B
- Net incomeUSD 303.00M
- Free cash flowUSD 48.00M
- Gross margin92.7%
Valuation Snapshot
latest market cap is USD 20.51B; P/E is 27.2.
Peer valuation comparison
Latest P/E is 27.21x versus a Healthcare sector median of 24.46x (11.2% above).
Latest P/E is 27.21x versus a Denmark median of 19.06x (42.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.72B | USD 963.00M | USD 1.13B | 93.6% | 3.04 | USD 1.72B | USD 5.43B | USD 5.85B |
| FY2024 | USD 2.94B | USD 1.08B | USD 1.02B | 95.4% | 13.03 | USD 1.38B | USD 144.00M | USD 5.14B |
| FY2023 | n/a | n/a | USD 7.00B | n/a | 12.14 | USD 14.87B | USD 770.00M | USD 31.61B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 20.51B | 27.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 18.97B | 19.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.26B | 11.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 20.80B | 34.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 27.95B | 35.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 26.00B | 54.9 | n/a | n/a |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genmab's market cap?
Genmab's market capitalization is USD 20.51B.
What is Genmab's P/E ratio?
Genmab's price-to-earnings (P/E) ratio is 27.2.
What does Genmab do?
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.